NovaBridge Biosciences (FRA:0VY) Valuation Rank


FRA:0VY NovaBridge Biosciences FRA:0VY
42 GF Score
Price €1.61
GF Value €38.31
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is NovaBridge Biosciences Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NovaBridge Biosciences Valuation Rank Related Terms

FRA:0VY
42GF Score
NovaBridge Biosciences FRA:0VY
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NovaBridge Biosciences (FRA:0VY) Overvalued in 2026?

Based on GuruFocus' analysis, NovaBridge Biosciences stock appears to be undervalued. The current stock price of €1.61 is trading 95.8% below its estimated GF Value™ of €38.31. GuruFocus considers NovaBridge Biosciences to be Possible Value Trap.

Key valuation signals for FRA:0VY:

  • Valuation Rank:
  • GF Value™: €38.31 vs. price of €1.61 (95.8% below fair value)
  • GF Score™: 42/100 with 2 warning signs

No single metric tells the full story. See the FRA:0VY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovaBridge Biosciences Business Description

Other Exchanges NBP:USA
Address 2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
42GF Score

Get the complete analysis for FRA:0VY

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.61
Price
€38.31
GF Value